Nykode Therapeutics AS (OSL:NYKD)

Norway flag Norway · Delayed Price · Currency is NOK
1.742
-0.084 (-4.60%)
Aug 1, 2025, 4:25 PM CET
-4.60%
Market Cap568.84M
Revenue (ttm)87.09M
Net Income (ttm)-266.37M
Shares Out326.55M
EPS (ttm)-0.83
PE Ration/a
Forward PEn/a
Dividend1.00 (54.76%)
Ex-Dividend DateMay 27, 2025
Volume671,590
Average Volume458,704
Open1.760
Previous Close1.826
Day's Range1.720 - 1.772
52-Week Range1.550 - 15.340
Beta1.16
RSI39.19
Earnings DateAug 27, 2025

About Altus Power

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 136
Stock Exchange Oslo Børs
Ticker Symbol NYKD
Full Company Profile

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial Statements

News

There is no news available yet.